230 related articles for article (PubMed ID: 18321240)
1. Ixabepilone for the treatment of solid tumors: a review of clinical data.
Denduluri N; Swain SM
Expert Opin Investig Drugs; 2008 Mar; 17(3):423-35. PubMed ID: 18321240
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
[TBL] [Abstract][Full Text] [Related]
4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
6. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone (Ixempra) for breast cancer.
Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
[No Abstract] [Full Text] [Related]
8. Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.
Goodin S
Am J Health Syst Pharm; 2008 Nov; 65(21):2017-26. PubMed ID: 18945860
[TBL] [Abstract][Full Text] [Related]
9. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
10. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with epothilones in patients with breast cancer.
Buzdar AU
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
[TBL] [Abstract][Full Text] [Related]
12. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
13. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
14. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.
Vahdat LT; Thomas ES; Roché HH; Hortobagyi GN; Sparano JA; Yelle L; Fornier MN; Martín M; Bunnell CA; Mukhopadhyay P; Peck RA; Perez EA
Support Care Cancer; 2012 Nov; 20(11):2661-8. PubMed ID: 22382588
[TBL] [Abstract][Full Text] [Related]
16. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Villanueva C; Dufresne A; Pivot X; Viel E
Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
[TBL] [Abstract][Full Text] [Related]
20. Epothilones in breast cancer: review of clinical experience.
Fornier MN
Ann Oncol; 2007 Jul; 18 Suppl 5():v16-21. PubMed ID: 17656557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
